scholarly journals Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study

EP Europace ◽  
2018 ◽  
Vol 21 (2) ◽  
pp. 313-321 ◽  
Author(s):  
Yung-Lung Chen ◽  
Yu-Sheng Lin ◽  
Hui-Ting Wang ◽  
Wen-Hao Liu ◽  
Huang-Chung Chen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Atrial Flutter ◽  
Clinical Outcomes ◽  
Anticoagulation Therapy ◽  
National Cohort

Asthma During Pregnancy and Clinical Outcomes in Offspring: A National Cohort Study

PEDIATRICS ◽  
2013 ◽  
Vol 132 (3) ◽  
pp. 483-491 ◽  
Author(s):  
M. Tegethoff ◽  
J. Olsen ◽  
E. Schaffner ◽  
G. Meinlschmidt
Keyword(s):  
Cohort Study ◽  
Clinical Outcomes ◽  
National Cohort

scholarly journals Proton-pump inhibitors do not influence clinical outcomes in patients with Staphylococcus aureus bacteremia

2019 ◽  
Vol 12 ◽  
pp. 175628481983427 ◽  
Author(s):  
Aisling R. Caffrey ◽  
Tristan T. Timbrook ◽  
Syed Raza Ali ◽  
Victor Nizet ◽  
George Sakoulas
Keyword(s):  
Staphylococcus Aureus ◽  
Cohort Study ◽  
Clinical Outcomes ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
De Novo ◽  
Culture Collection ◽  
Staphylococcus Aureus Bacteremia ◽  
Increased Risk ◽  
National Cohort

Background: Proton-pump inhibitors (PPIs) are commonly used in clinical practice for gastric acid suppression. However, these agents have also been associated with certain negative clinical outcomes. We evaluated the real-world effects of incident PPI use on clinical outcomes in patients with Staphylococcus aureus bacteremia. Methods: This retrospective cohort study included patients admitted to Veterans Affairs hospitals with positive S. aureus blood cultures collected between 2002 and 2013 that received appropriate antibiotics within 48 hours of culture collection. Clinical outcomes among three PPI exposure groups, each compared to nonusers, were assessed with propensity-score-matched Cox proportional-hazard regression models: pretreated PPI users initiating therapy in the 30 days prior to culture and either (a) continuing PPI therapy after culture, or (b) not continuing after culture, and (c) de novo users initiating at culture. Results: Clinical outcomes, including inpatient mortality, intensive care discharge, 30-day mortality, 30-day readmission, and 30-day Clostridium difficile infection (CDI) were similar among PPI users and nonusers. Though length of stay was longer in pretreated, continuing PPI users [time-to-discharge hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.65–0.93], 14-day mortality was significantly lower than in nonusers (HR 0.66, 95% CI 0.50–0.87). Conclusions: In our large national cohort study, PPIs were not associated with an increased risk of negative clinical outcomes, including mortality and CDI, in patients with S. aureus bacteremia.

Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2299-2299
Author(s):  
Karine Gauthier ◽  
Elham Sabri ◽  
Susan R. Kahn ◽  
Philip S Wells ◽  
David Anderson ◽  
...  
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Family History ◽  
Conflicts Of Interest ◽  
Anticoagulation Therapy ◽  
Degree Relative ◽  
National Cohort ◽  
History Of ◽  
Recurrent Vte ◽  
Second Degree

Abstract Abstract 2299 Introduction: The duration of anticoagulation after unprovoked venous thromboembolism (VTE) has been characterized as the most important unanswered question in clinical thrombosis management. This has led to research to identify predictors of recurrent VTE to identify high-risk patients who might warrant indefinite anticoagulation. Many clinicians assume that a family history of VTE is a predictor of recurrent VTE. This study aims to assess the value of family history as a predictor for recurrent VTE. Methods: Prospective multi-center multi-national cohort study recruited patients with a first objectively proven unprovoked VTE who completed 5 to 7 months of anticoagulation therapy. A detailed family history of VTE was completed for every subject. The information recorded included the number of affected relatives, whether they were first or second degree relatives and if the VTE was unprovoked or secondary. Patients were then followed for recurrent VTE. Results: 664 subjects were enrolled between October 2001 and March 2006, 649 subjects were followed for a mean duration of 3.8 years (3.6–3.98 95% C.I.). The mean age of subjects in this cohort was 53 years (min-max 18–95) and 49% of subjects were females. A family history of VTE in at least 1 first-degree relative was recorded for 112 (17.3%) subjects. A total of 142 (21.9%) suspected VTE events were adjudicated as recurrences. The recurrence rate was 5.94% (4.89–7.15 95% C.I.) per patient-year for patients without any family history of VTE, and it was 4.82% (3.02–7.30 95% C.I.) per patient-year in patients with a family history of VTE in at least 1 first-degree relative. In secondary analyses, neither a family history of unprovoked VTE, multiple unprovoked VTE, in first-degree nor second-degree relatives was a predictor of recurrent VTE. A multivariate analysis was performed to adjust for known risk factors for VTE recurrence, but the adjusted hazard ratios were again not significantly different. Conclusion: A family history of VTE is not a predictor for recurrent VTE, and therefore should not be used to segregate unprovoked VTE patients in high- and low-risk categories. Disclosures: No relevant conflicts of interest to declare.

Asthma During Pregnancy and Clinical Outcomes in Offspring: A National Cohort Study

PEDIATRICS ◽  
2014 ◽  
Vol 134 (Supplement) ◽  
pp. S165-S165
Author(s):  
P. Davoodi ◽  
W. K. Dolen
Keyword(s):  
Cohort Study ◽  
Clinical Outcomes ◽  
National Cohort

scholarly journals Corrigendum: Differential Risk of Dementia Between Patients With Atrial Flutter and Atrial Fibrillation: A National Cohort Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Hui-Ting Wang ◽  
Yung-Lung Chen ◽  
Yu-Sheng Lin ◽  
Huang-Chung Chen ◽  
Shaur-Zheng Chong ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Study ◽  
Atrial Flutter ◽  
National Cohort ◽  
Differential Risk

Evaluation of Clinical Outcomes After Revascularization in Patients With Chronic Limb-Threatening Ischemia: Results From a Prospective National Cohort Study (RIVALUTANDO)

Angiology ◽  
2021 ◽  
pp. 000331972098061
Author(s):  
Gianmarco de Donato ◽  
Filippo Benedetto ◽  
Francesco Stilo ◽  
Roberto Chiesa ◽  
Domenico Palombo ◽  
...  
Keyword(s):  
Cohort Study ◽  
Clinical Outcomes ◽  
Protective Factor ◽  
Primary Patency ◽  
Multicenter Cohort Study ◽  
Below The Knee ◽  
National Cohort ◽  
Iloprost Infusion ◽  
Lower Extremity Revascularization

We evaluated the outcomes of revascularization in patients with chronic limb-threatening ischemia (CLTI) treated in real-world settings. This is a prospective multicenter cohort study with 12-month follow-up enrolling patients (n = 287) with CLTI undergoing open, endovascular, or hybrid lower extremity revascularization. The primary end point was amputation-free survival (AFS) at 12 months. Cox proportional analysis was used to determine independent predictors of amputation and restenosis. At 30 days, major adverse cardiovascular and major adverse limb events (MALE) rates were 3.1% and 2.1%, respectively. At 1 year, the overall survival rate was 88.8%, the AFS was 86.6%, and the primary patency was 70.5%. Freedom from MALE was 62.5%. After multivariate analysis, smoking (hazard ratio [HR] = 2.2, P = 0.04), renal failure (HR = 2.3, P = 0.03), Rutherford class (≥5) (HR = 3.2, P = 0.01), and below-the-knee disease (HR = 2.0, P = 0.05) were significant predictors of amputation; iloprost infusion (>10 vials) (HR = 0.64, P = 0.05) was a significant protective factor. Cilostazol administration (HR = 0.77, P = 0.05) was a significant protective factor for restenosis. Results from this prospective multicenter registry offer a consistent overview of clinical outcomes of CLTI patients at 1 year when adequately revascularized. Medical treatment, including statins, cilostazol and iloprost, were associated with improved 1-year freedom from restenosis and amputation.

Sign in / Sign up

Export Citation Format

Share Document